Eli Lilly and Company (LLY)vsYD Bio Ltd (YDES)
LLY
Eli Lilly and Company
$1,131.42
+0.32%
HEALTHCARE · Cap: $1.01T
YDES
YD Bio Ltd
$3.01
-4.29%
HEALTHCARE · Cap: $171.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 14156378% more annual revenue ($72.25B vs $510,360). LLY leads profitability with a 35.0% profit margin vs -276.6%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
YDES
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Revenue surging 95.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -42.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : YDES
The strongest argument for YDES centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 95.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : YDES
The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while YDES is a hypergrowth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.52 — expect wider price swings.
YDES is growing revenue faster at 95.6% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 21/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →YD Bio Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?